Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 15NIH 11NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 3Colorectal Neoplasms 2Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 27Carboplatin 23Cisplatin 16Topotecan 8Taxes 8Docetaxel 7Gemcitabine 6Filgrastim 5Etoposide 4Doxorubicin 4Cyclophosphamide 4Psychiatric Rehabilitation 3Ifosfamide 3Chemotherapy, Adjuvant 3rubitecan 2pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Trabectedin 2Surgical Procedures, Operative 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Irinotecan 2GEN-1 2Fenretinide 2Erlotinib Hydrochloride 2Drug Therapy 2Celecoxib 2Bevacizumab 2Amifostine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ovarian Neoplasms × Disulfides × Clear all
NCT00886691 2022-02-04

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
150 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡